Acacia Amaranthus Hybridus Leaf Amaranthus Tubercu

證據等級: L5

預測適應症: 0 個

Multi-Allergen Corticotropin Complex: Allergy Diagnostic Panel — No Repurposing Prediction Available

One-Sentence Summary

This product is a complex multi-component allergen mixture containing 30 biological and botanical constituents — including tree/weed/grass pollens, animal-derived extracts, CORTICOTROPIN (ACTH), and HISTAMINE DIHYDROCHLORIDE — consistent with an allergy skin-testing panel used for diagnosing allergic sensitivities. The TxGNN model did not generate any repurposing predictions for this candidate, and no predicted new indication is available. There is therefore no evidence to evaluate in the standard drug repurposing framework at this time.

Quick Overview

Item	Content
Original Indication	Not established (no regulatory authorizations found)
Predicted New Indication	None — TxGNN returned no predictions
TxGNN Prediction Score	N/A
Evidence Level	L5 (model prediction only — and no prediction was generated)
US Market Status	Not marketed (0 authorizations on record)
Number of NDAs	0
Recommended Decision	Hold

Why No Prediction is Available

This candidate’s INN is a semicolon-delimited list of 30 distinct biological ingredients, including:

Multiple aeroallergens: Ragweed (Ambrosia artemisiifolia), bermuda grass (Cynodon dactylon), birch (Betula occidentalis), oak (Quercus kelloggii), elm, ash, poplar, pine, juniper, and others
Food/environmental allergens: English walnut, white mulberry, beef liver, alfalfa (Medicago sativa)
Skin-test controls: HISTAMINE DIHYDROCHLORIDE (standard positive control) and CORTICOTROPIN (ACTH, used as a reference antigen in some panels)
Other botanicals: Acacia, sage, cocklebur, Brazilian pepper tree pollen

The composition strongly suggests this is an allergen immunotherapy diagnostic panel or an allergy skin-prick test kit, rather than a single pharmaceutical entity suitable for drug repurposing analysis.

TxGNN operates on single-drug nodes mapped via DrugBank IDs. Because:

No DrugBank ID could be resolved for this multi-component mixture
The 30 ingredients do not map to a unified drug node in the knowledge graph
No approved indication exists as an anchor for repurposing search

…the pipeline produced no predictions. Without a defined original indication or a mappable drug node, repurposing analysis cannot proceed.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: This candidate is a complex multi-component allergen mixture with no DrugBank mapping, no approved indication, and no TxGNN output. The standard repurposing pipeline cannot be applied to a product of this type in its current form.

To proceed, the following is needed:

Clarify the candidate identity: Confirm whether the intent is to analyze a specific single active ingredient within this mixture (e.g., CORTICOTROPIN/ACTH as a standalone drug) rather than the mixture as a whole.
Resolve DrugBank mapping: If CORTICOTROPIN is the target, query DrugBank with INN “corticotropin” (DB00836) to obtain a valid drug node for TxGNN.
Define original indication: ACTH/corticotropin has established indications (infantile spasms, diagnostic adrenocortical insufficiency testing); these would serve as the repurposing anchor.
Re-run TxGNN against the resolved single-drug node to obtain repurposing candidates.
Taiwan regulatory check: Confirm whether any component of this mixture holds a separate TFDA authorization (e.g., corticotropin injection).

Note: If the goal is allergen immunotherapy repurposing research, a different evidence framework (allergen-specific immunology databases, EAACI guidelines) should be used rather than the TxGNN small-molecule repurposing pipeline.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.